



(12) Translation of
European patent specification

(11) NO/EP 3009428 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/12 (2006.01)
A61K 31/497 (2006.01)
A61P 35/02 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.06.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.02.21
(86)	European Application Nr.	15189570.3
(86)	European Filing Date	2010.05.06
(87)	The European Application's Publication Date	2016.04.20
(30)	Priority	2009.05.08, JP, 2009113936
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	RS
(62)	Divided application	EP2428508, filing date 2010.05.06
(73)	Proprietor	Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-kuTokyo 103-8411, JP-Japan Kotobuki Pharmaceutical Co., Ltd., 6351, Oaza-Sakaki, Sakaki-machi, Hanishina-gun, Nagano 389-0697, JP-Japan
(72)	Inventor	Shimada, Itsuro, c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho 2-chomeChuo-ku, Tokyo, 103-8411, JP-Japan Kurosawa, Kazuo, c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho 2-chomeChuo-ku, Tokyo, 103-8411, JP-Japan Matsuya, Takahiro, c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho 2-chomeChuo-ku, Tokyo, 103-8411, JP-Japan Iikubo, Kazuhiko, c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho 2-chomeChuo-ku, Tokyo, 103-8411, JP-Japan Kondoh, Yutaka, c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho 2-chomeChuo-ku, Tokyo, 103-8411, JP-Japan Kamikawa, Akio, c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho 2-chomeChuo-ku, Tokyo, 103-8411, JP-Japan Tomiyama, Hiroshi, c/o KOTOBUKI PHARMACEUTICAL CO., LTD.6351 Oaza-Sakaki, Sakaki-machi, Hanishina-gun,, Nagano 389-0697, JP-Japan Iwai, Yoshinori, c/o KOTOBUKI PHARMACEUTICAL CO., LTD.6351 Oaza-Sakaki, Sakaki-machi, Hanishina-gun,, Nagano 389-0697, JP-Japan

(74) Agent or Attorney

BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND**

(56) References

Cited: CA-A1- 2 692 611, WO-A2-2008/016660

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse eller et salt derav for anvendelse i en fremgangsmåte for å forebygge og/eller behandle akutt myelocytisk leukemi eller atypisk kronisk myelocytisk leukemi, hvor nevnte forbindelse er:
- 5 6-etyl-3-(3-metoksy-4-[4-(4-metylpiperazin-1-yl)piperidin-1-yl]fenyl)amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazin-2-karboksamid.
2. Forbindelsen eller et salt derav for anvendelse ifølge krav 1, hvor forbindelsen eller et salt derav er:
- 10 6-etyl-3-(3-metoksy-4-[4-(4-metylpiperazin-1-yl)piperidin-1-yl]fenyl)amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazin-2-karboksamidhemifumarsyresalt.
3. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 2, som
- 15 anvendes i en fremgangsmåte for å forebygge og/eller behandle mutant FLT3 polynukleotid-positiv akutt myelocytisk leukemi, FLT3 fusjonspolynukleotid-positiv atypisk kronisk myelocytisk leukemi, akutt myelocytisk leukemi med FLT3 intern tandem duplikasjonsmutasjon og/eller akutt myelocytisk leukemi med FLT3 aktiv punktmutasjon.